The Practitioner’s Guide to Psychoactive Drugs

1. Front Matter

   Pages i-xxxi

   PDF

2. State of the Art

   1. Front Matter

      Pages 1-1

      PDF

   2. Introduction: The Practice of Pharmacotherapy

      • Stephen C. Schoonover, Alan J. Gelenberg

      Pages 3-19

3. Major Psychiatric Disorders

   1. Front Matter

      Pages 21-21

      PDF

   2. Depression

      • Alan J. Gelenberg, Stephen C. Schoonover

      Pages 23-89

   3. Bipolar Disorder

      • Alan J. Gelenberg, Stephen C. Schoonover

      Pages 91-123

   4. Psychoses

      • Alan J. Gelenberg

      Pages 125-178

   5. Anxiety

      • Jerrold F. Rosenbaum, Alan J. Gelenberg

      Pages 179-218

   6. Insomnia

      • Jeffrey B. Weilburg, Alan J. Gelenberg

      Pages 219-240

4. Psychoactive Substance Abuse

   1. Front Matter

      Pages 241-241

      PDF

   2. Psychoactive Substance Use Disorders

      • Steven M. Mirin, Roger D. Weiss, Shelly F. Greenfield

      Pages 243-316

5. Special Topics

   1. Front Matter

      Pages 317-317

      PDF

   2. Geriatric Psychopharmacology

      • Carl Salzman

      Pages 319-339

   3. Pediatric Psychopharmacology

      • Joseph Biederman, Ronald Steingard

      Pages 341-388

   4. Psychotropic Drug Use in Pregnancy

      • Lee S. Cohen, Jerrold F. Rosenbaum, Vicki L. Heller

      Pages 389-405

   5. Temporolimbic Epilepsy

      • Jeffrey B. Weilburg, George B. Murray

      Pages 407-438

   6. Eating Disorders

      • Andrew W. Brotman, David B. Herzog

      Pages 439-455

   7. Borderline Disorders

      • Paul H. Soloff

      Pages 457-472

   8. Medicolegal Psychopharmacology

      • Thomas G. Gutheil

      Pages 473-485

6. Back Matter

   Pages 487-504

   PDF

In the eight years since the publication of the second edition of this Guide, psycho­ phannacotherapy has made many advances not only through the discovery of new medications but by the effective directing of their use to an ever-increasing variety of clinical disorders. These welcome developments are reflected in the concurrent growth and development of the Guide itself, which now enters adulthood with renewed vigor. Under the thoughtful and scholarly leadership of Dr. Alan Gelenberg, the third edition has undergone a significant transformation designed to meet the needs of the modem clinician. The panel of contributors is nearly double that of the former edition with the addition of nine new authors, who have helped in the major revision and rewriting of the text and in a broadening of the topics included. As a conse­ quence, the reader is assured of a thorough and thoroughly up-to-date coverage of current psychopharmacology that is both accurate and aimed at clinical utility. Having reached maturity, the third edition, while maintaining the lineaments of its earlier versions, is a considerably expanded and strengthened guide to treatment. Although now more encyclopedic in content, the new Practitioner' s Guide to Psy­ choactive Drugs retains the virtues of a clinical vade mecum that informed its predecessors and have eamed it a place by the patient's bedside for weIl over a decade. One may confidently anticipate its long and flourishing career in the years ahead. John C. Nemiah, M.D.

• development
• growth
• pharmacology
• therapy

• University of Arizona Health Sciences Center, Tucson, USA

  Alan J. Gelenberg

• The Better Homes Foundation, Newton Centre, USA

  Ellen L. Bassuk

• Harvard Medical School, Boston, USA

  Ellen L. Bassuk

• Schoonover Associates, Newton Centre, USA

  Stephen C. Schoonover

Policies and ethics